Overview NF-κB Inhibition in Amyotrophic Lateral Sclerosis Status: Not yet recruiting Trial end date: 2022-09-01 Target enrollment: Participant gender: Summary This is a Phase II, single centre, randomized, parallel, double blind, placebo-controlled clinical trial to determine the safety of Withania somnifera in participants with Amyotrophic Lateral Sclerosis (ALS). Phase: Phase 2 Details Lead Sponsor: Sunnybrook Health Sciences Centre